{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:31:55Z","timestamp":1793665915750,"version":"4.5.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmoop.2025.104292","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T15:04:36Z","timestamp":1739631876000},"page":"104292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study"],"prefix":"10.1016","volume":"10","author":[{"given":"D.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gjoreski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-0568","authenticated-orcid":false,"given":"S.","family":"Spiliopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-8154","authenticated-orcid":false,"given":"T.","family":"Helmberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-9819","authenticated-orcid":false,"given":"F.M.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"de Ba\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-6607","authenticated-orcid":false,"given":"O.","family":"Pellerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Maleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-7352","authenticated-orcid":false,"given":"H.","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6417","authenticated-orcid":false,"given":"B.","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4823-6923","authenticated-orcid":false,"given":"N.C.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.104292_bib1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jcmgh.2023.08.012","article-title":"Updated management of colorectal cancer liver metastases: scientific advances driving modern therapeutic innovations","volume":"16","author":"Patel","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2025.104292_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib3","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3748\/wjg.15.449","article-title":"Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients","volume":"15","author":"Moehler","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.esmoop.2025.104292_bib5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2025.104292_bib7","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.3390\/curroncol30060397","article-title":"A\u00a0systematic review and meta-analysis of trifluridine\/tipiracil plus bevacizumab for the treatment of metastatic colorectal cancer: evidence from real-world series","volume":"30","author":"Voutsadakis","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.6004\/jnccn.2022.7082","article-title":"A\u00a0real-world comparison of regorafenib and trifluridine\/tipiracil in refractory metastatic colorectal cancer in the United States","volume":"21","author":"Nevala-Plagemann","year":"2023","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.esmoop.2025.104292_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer \u2013 beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2025.104292_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.esmoop.2025.104292_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejps.2006.09.002","article-title":"Irinotecan drug eluting beads for use in chemoembolization: in\u00a0vitro and in\u00a0vivo evaluation of drug release properties","volume":"30","author":"Taylor","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.esmoop.2025.104292_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jvir.2010.02.042","article-title":"Comparative study of chemoembolization loadable beads: in\u00a0vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan","volume":"21","author":"Jordan","year":"2010","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bulcan.2016.10.025","article-title":"Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded)","volume":"104","author":"de Baere","year":"2017","journal-title":"Bull Cancer"},{"key":"10.1016\/j.esmoop.2025.104292_bib14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jvir.2013.05.055","article-title":"Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review","volume":"24","author":"Richardson","year":"2013","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib15","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1007\/s00432-021-03708-1","article-title":"Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens","volume":"147","author":"Cao","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s00270-021-03039-1","article-title":"Small-size (40 \u03bcm) beads loaded with irinotecan in the treatment of patients with colorectal liver metastases","volume":"45","author":"Mauri","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s00268-015-3386-9","article-title":"Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases","volume":"40","author":"Bhutiani","year":"2016","journal-title":"World J Surg"},{"key":"10.1016\/j.esmoop.2025.104292_bib18","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/cncr.29534","article-title":"Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis","volume":"121","author":"Martin","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2025.104292_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41416-020-0917-4","article-title":"Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a phase 2 study","volume":"123","author":"Pernot","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.104292_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.5152\/dir.2021.20520","article-title":"Combination of ablation and embolization for intermediate-sized liver metastases from colorectal cancer: what can we learn from treating primary liver cancer?","volume":"27","author":"Seager","year":"2021","journal-title":"Diagnostic Interv Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.dld.2020.05.051","article-title":"A\u00a0multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: design and rationale of CIREL","volume":"52","author":"Pereira","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.esmoop.2025.104292_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00270-020-02646-8","article-title":"The CIREL cohort: a prospective controlled registry studying the real-life use of irinotecan-loaded chemoembolisation in colorectal cancer liver metastases: interim analysis","volume":"44","author":"Pereira","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib23","first-page":"1","article-title":"Safety, feasibility and technical considerations from a prospective, observational study\u2013CIREL: irinotecan-TACE for CRLM in 152 patients","volume":"11","author":"Helmberger","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.esmoop.2025.104292_bib24","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.esmoop.2025.104292_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10269-006-0412-4","article-title":"Quality of life assessment and research in the EORTC (European Organisation for Research and Treatment of Cancer)","volume":"8","author":"Flechtner","year":"2006","journal-title":"Oncologie"},{"key":"10.1016\/j.esmoop.2025.104292_bib26","first-page":"7239","article-title":"Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer","volume":"34","author":"Akinwande","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2025.104292_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/cancers15020541","article-title":"Efficacy of liver chemoembolization after prior cetuximab monotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Szemitko","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.104292_bib28","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00270-015-1080-9","article-title":"Trans-arterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a phase II single-center study","volume":"38","author":"Iezzi","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib29","first-page":"1387","article-title":"Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study","volume":"32","author":"Fiorentini","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2025.104292_bib30","first-page":"4581","article-title":"Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead\u00ae, drug-eluting bead loaded with irinotecan: results of a phase II clinical study","volume":"31","author":"Aliberti","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2025.104292_bib31","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s00270-023-03446-6","article-title":"Prospective series of transarterial chemoembolization of metastatic colorectal cancer to the liver with 30\u201360 \u03bcm microspheres loaded with irinotecan","volume":"46","author":"Malagari","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4251\/wjgo.v7.i6.47","article-title":"Locoregional therapy and systemic cetuximab to treat colorectal liver metastases","volume":"7","author":"Fiorentini","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib33","first-page":"1","article-title":"Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization","volume":"34","author":"Scevola","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib34","first-page":"683","article-title":"Chemoembolization alone or associated with bevacizumab for therapy of colorectal cancer metastases: preliminary results of a randomized study","volume":"34","author":"Fiorentini","year":"2020","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.esmoop.2025.104292_bib35","first-page":"3413","article-title":"Early experience with 70-150 m irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases","volume":"36","author":"Akinwande","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2025.104292_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.suronc.2017.05.003","article-title":"Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review","volume":"26","author":"Akinwande","year":"2017","journal-title":"Surg Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib37","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jvir.2018.08.010","article-title":"Irinotecan-eluting 75-150-\u03bcm embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center phase I study","volume":"29","author":"Fereydooni","year":"2018","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.esmoop.2025.104292_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1245\/s10434-010-1288-5","article-title":"Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study","volume":"18","author":"Martin","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/0284186X.2014.938830","article-title":"Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials","volume":"54","author":"Giessen","year":"2015","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.esmoop.2025.104292_bib40","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4143\/crt.2016.249","article-title":"Surrogate endpoints in second-line trials of targeted agents in metastatic colorectal cancer: a literature-based systematic review and meta-analysis","volume":"49","author":"Cremolini","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2025.104292_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers15184603","article-title":"Real-world outcomes in patients with metastatic colorectal cancer in Spain: the RWD-ACROSS study","volume":"15","author":"Pericay","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.104292_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdy038","article-title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","volume":"29","author":"Arnold","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib43","first-page":"1","article-title":"Survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program","volume":"16","author":"Adenis","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2025.104292_bib44","first-page":"4299","article-title":"Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies","volume":"36","author":"Sueda","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2025.104292_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","article-title":"Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum multicenter observational study","volume":"23","author":"Moriwaki","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2025.104292_bib46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11523-022-00916-8","article-title":"Real-world activity and safety of trifluridine-tipiracil plus bevacizumab therapy in patients with refractory metastatic colorectal cancer","volume":"17","author":"Arrichiello","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-18871-9","article-title":"Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine\/tipiracil plus bevacizumab in a real-world setting","volume":"12","author":"Mart\u00ednez-Lago","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2025.104292_bib48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-020-04129-6","article-title":"Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD\/TPI plus bevacizumab: a retrospective study","volume":"86","author":"Nose","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2025.104292_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211009143","article-title":"Efficacy and safety of trifluridine\/tipiracil plus bevacizumab and trifluridine\/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study","volume":"13","author":"Chida","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3892\/ol.2021.13044","article-title":"Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine\/tipiracil plus bevacizumab","volume":"22","author":"Kamiimabeppu","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.esmoop.2025.104292_bib51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S1470-2045(20)30009-7","article-title":"TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?","volume":"21","author":"Eng","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102202","article-title":"Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis of individual patients\u2019 data from 3 phase III studies","volume":"97","author":"Salvatore","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2025.104292_bib53","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdx322","article-title":"Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study","volume":"28","author":"Goey","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib54","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/annonc\/mdw101","article-title":"Single-agent capecitabine as maintenance therapy afterinduction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety","volume":"27","author":"Luo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib55","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4251\/wjgo.v9.i9.379","article-title":"Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer","volume":"9","author":"Fiorentini","year":"2017","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2025.104292_bib57","first-page":"1085","article-title":"Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study","volume":"21","author":"Fiorentini","year":"2007","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.esmoop.2025.104292_bib58","article-title":"Case report and literature review: PET\/CT in the evaluation of response to treatment of liver metastasis from colorectal cancer with DEBIRI-TACE","volume":"13","author":"Jin","year":"2023","journal-title":"Front Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925001607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925001607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:28Z","timestamp":1762598668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925001607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2059702925001607"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104292","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104292"}}